JP2019524701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524701A5 JP2019524701A5 JP2019500245A JP2019500245A JP2019524701A5 JP 2019524701 A5 JP2019524701 A5 JP 2019524701A5 JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019524701 A5 JP2019524701 A5 JP 2019524701A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antagonist
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359073P | 2016-07-06 | 2016-07-06 | |
| US62/359,073 | 2016-07-06 | ||
| PCT/US2017/040665 WO2018009507A1 (en) | 2016-07-06 | 2017-07-05 | Combination of tim-4 antagonist and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524701A JP2019524701A (ja) | 2019-09-05 |
| JP2019524701A5 true JP2019524701A5 (https=) | 2020-08-13 |
| JP7164512B2 JP7164512B2 (ja) | 2022-11-01 |
Family
ID=59366515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500245A Active JP7164512B2 (ja) | 2016-07-06 | 2017-07-05 | Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11306143B2 (https=) |
| EP (1) | EP3481866B1 (https=) |
| JP (1) | JP7164512B2 (https=) |
| KR (1) | KR102602137B1 (https=) |
| CN (1) | CN109641968B (https=) |
| ES (1) | ES2992868T3 (https=) |
| WO (1) | WO2018009507A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| KR102602137B1 (ko) | 2016-07-06 | 2023-11-13 | 브리스톨-마이어스 스큅 컴퍼니 | Tim-4 길항제 및 pd-1 길항제의 조합물 및 사용 방법 |
| WO2021064184A1 (en) * | 2019-10-04 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
| CN110982824B (zh) * | 2019-10-09 | 2022-04-15 | 天津大学 | 拮抗pd-1的抗体类似物bp基因及蛋白和应用 |
| US11774451B2 (en) * | 2019-11-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular vibrational spectroscopic markers for detection of cancer |
| US20250177340A1 (en) * | 2021-01-29 | 2025-06-05 | Lapix Therapeutics, Inc. | Tartaric Acid Analogs and Uses Thereof |
| WO2023019137A1 (en) * | 2021-08-10 | 2023-02-16 | Heat Biologics, Inc. | Generation and characterization of novel tim-4 binding agents |
| JP7804370B2 (ja) | 2021-08-13 | 2026-01-22 | ラピックス セラピューティクス， インコーポレイテッド | 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法 |
| CN115957304A (zh) * | 2022-10-18 | 2023-04-14 | 山东大学 | Tim-4调控胆固醇合成中的应用 |
| CN120530142A (zh) * | 2023-01-13 | 2025-08-22 | 上海凯今生物科技有限公司 | 多特异性多肽复合物 |
| WO2025077833A1 (en) * | 2023-10-11 | 2025-04-17 | Suzhou Neologics Bioscience Co., Ltd. | Antibodies targeting tim-3 and pd-1 and uses thereof |
| CN117904122B (zh) * | 2023-12-22 | 2025-01-28 | 北京贝来药业有限公司 | 一种编码抗pd-1抗体的基因及其修饰干细胞的制备和应用 |
| WO2026067461A1 (en) * | 2024-09-25 | 2026-04-02 | Adaptocue, Llc | Multispecific antibody protein and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| HUT76369A (en) | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| CN101035561A (zh) * | 2004-03-24 | 2007-09-12 | 特罗斯药品公司 | 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) * | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JP2015209376A (ja) * | 2014-04-24 | 2015-11-24 | 国立大学法人北海道大学 | 腫瘍特異的免疫増強剤 |
| KR102602137B1 (ko) | 2016-07-06 | 2023-11-13 | 브리스톨-마이어스 스큅 컴퍼니 | Tim-4 길항제 및 pd-1 길항제의 조합물 및 사용 방법 |
-
2017
- 2017-07-05 KR KR1020197003493A patent/KR102602137B1/ko active Active
- 2017-07-05 CN CN201780054101.9A patent/CN109641968B/zh active Active
- 2017-07-05 JP JP2019500245A patent/JP7164512B2/ja active Active
- 2017-07-05 US US16/314,732 patent/US11306143B2/en active Active
- 2017-07-05 WO PCT/US2017/040665 patent/WO2018009507A1/en not_active Ceased
- 2017-07-05 EP EP17740851.5A patent/EP3481866B1/en active Active
- 2017-07-05 ES ES17740851T patent/ES2992868T3/es active Active
-
2022
- 2022-03-14 US US17/693,975 patent/US12227575B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524701A5 (https=) | ||
| JP2016537383A5 (https=) | ||
| JP2020055853A5 (https=) | ||
| JP2019510733A5 (https=) | ||
| JP2017524715A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2017048240A5 (https=) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018070648A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| JP2018532383A5 (https=) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2017500057A5 (https=) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2018508483A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2023504016A5 (https=) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2017513900A5 (https=) | ||
| JP2014522850A5 (https=) | ||
| JP2018516911A5 (https=) |